Prognostic value of lymphocyte-to-monocyte ratio in patients with solid tumors: A systematic review and meta-analysis.

Abstract:

BACKGROUND:The immune system plays an important role in cancer pathogenesis. A low lymphocyte-to-monocyte ratio (LMR), as a simple biomarker of host immune system, has been suggested to be related to poor prognosis in various cancers. We performed a systematic review and meta-analysis to quantify the prognostic value of LMR on clinical outcomes in non-hematologic solid tumors. PATIENTS AND METHODS:We searched PubMed and the ASCO online database of meeting abstracts up to July 2015 for relevant studies. We included studies assessing the prognostic impact of pre-treatment LMR on clinical outcomes in patients with non-hematologic solid tumors. The primary outcome was overall survival (OS) and the secondary outcomes were cancer-specific survival (CSS) and disease-free survival (DFS). The summary hazard ratio (HR) and 95% confidence interval (CI) were calculated. RESULTS:A total of 11,197 patients from 29 studies were included. LMR lower than the cut-off was associated with poor OS (HR, 1.73; 95% CI, 1.55-1.93; P<0.001), CCS (HR, 1.56; 95% CI, 1.27-1.91; P<0.001) and DFS (HR, 1.56; 95% CI, 1.31-1.86; P<0.001). The effect of LMR on OS was observed in among various tumor types and across disease stages. The median cut-off value for LMR was 3.0 (range=2.0-5.3). Subgroup analysis according to cut-off value (<3.0, 3.0 to <4.0, 4.0 to <5.0, and ≧5.0) showed a significant prognostic value of LMR on OS in all subgroups. CONCLUSIONS:A low pre-treatment LMR seems to represent an unfavorable and robust prognostic factor for clinical outcomes in patients with non-hematologic malignancies. FUNDING:None.

journal_name

Cancer Treat Rev

journal_title

Cancer treatment reviews

authors

Nishijima TF,Muss HB,Shachar SS,Tamura K,Takamatsu Y

doi

10.1016/j.ctrv.2015.10.003

subject

Has Abstract

pub_date

2015-12-01 00:00:00

pages

971-8

issue

10

eissn

0305-7372

issn

1532-1967

pii

S0305-7372(15)00174-7

journal_volume

41

pub_type

杂志文章,meta分析,评审
  • Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-analysis of randomized controlled trials.

    abstract:BACKGROUND:A relationship between baseline tumor-infiltrating lymphocytes (TIL) and outcomes has been described in HER2-positive breast cancer. Nevertheless, the magnitude of this association and whether this effect differs based on the type of anti-HER2 agent remain controversial. This meta-analysis investigated the a...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,meta分析,评审

    doi:10.1016/j.ctrv.2017.04.005

    authors: Solinas C,Ceppi M,Lambertini M,Scartozzi M,Buisseret L,Garaud S,Fumagalli D,de Azambuja E,Salgado R,Sotiriou C,Willard-Gallo K,Ignatiadis M

    更新日期:2017-06-01 00:00:00

  • Participation of adolescents with cancer in clinical trials.

    abstract::Adolescent patients with cancer reside in a "no-man's land" between the world of pediatric oncology and that of "adult" medical oncology. As compared to younger and older patients, adolescents and young adults are under-represented on clinical trials. This relative lack of participation in clinical protocols has been ...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2006.11.005

    authors: Ferrari A,Bleyer A

    更新日期:2007-11-01 00:00:00

  • Prostate-specific antigen kinetics as a surrogate endpoint in clinical trials of metastatic castration-resistant prostate cancer: a review.

    abstract::Prostate cancer is the most common cancer in men. Overall survival is considered the best endpoint for clinical trials, but it is difficult to use in phase-2 studies. Although the reduction of PSA after cytotoxic chemotherapy has been identified as a valid surrogate for overall survival, it has not proven reliable for...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2012.03.008

    authors: Colloca G

    更新日期:2012-12-01 00:00:00

  • Cardiovascular effects of breast cancer radiotherapy.

    abstract::Cardiac toxicity has been implicated as the primary reason for excess non-breast cancer mortality in early breast cancer radiotherapy studies. Refinements in radiotherapy techniques have allowed for a considerable reduction of this risk in the majority of breast cancer patients. Recent large population-based studies c...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2007.07.011

    authors: Senkus-Konefka E,Jassem J

    更新日期:2007-10-01 00:00:00

  • Evolving strategies for the treatment of hepatocellular carcinoma: from clinical-guided to molecularly-tailored therapeutic options.

    abstract::Hepatocellular carcinoma (hepatocellular carcinoma, HCC) is the commonest primary liver cancer (80-90%) and represents the leading cause of cancer-related death, after lung and stomach cancer. The process of neoplastic transformation proceeds through the accumulation of mutations in the genes governing cell proliferat...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2010.08.001

    authors: Faloppi L,Scartozzi M,Maccaroni E,Di Pietro Paolo M,Berardi R,Del Prete M,Cascinu S

    更新日期:2011-05-01 00:00:00

  • Malignant distal biliary obstruction: a systematic review and meta-analysis of endoscopic and surgical bypass results.

    abstract:BACKGROUND:Surgical bypass and endoscopic stents are available for palliative bypass of malignant distal biliary obstruction. AIM:Comparison of reported outcomes in randomized controlled trials (RCTs) which included surgery, endoscopic plastic stents or endoscopic metal stents in palliative relief of malignant distal ...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,meta分析,评审

    doi:10.1016/j.ctrv.2006.10.006

    authors: Moss AC,Morris E,Leyden J,MacMathuna P

    更新日期:2007-04-01 00:00:00

  • Irreversible pan-ErbB tyrosine kinase inhibitors and breast cancer: current status and future directions.

    abstract::Aberrant activation of HER2 through overexpression has been shown to play an important role in some breast cancers. Therapies against this receptor including the monoclonal antibody, trastuzumab, or the small tyrosine kinase inhibitor, lapatinib have shown to improve the prognosis of such patients. Despite overexpress...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2009.08.001

    authors: Ocaña A,Amir E

    更新日期:2009-12-01 00:00:00

  • Health promotion and psychological interventions for adolescent and young adult cancer survivors: A systematic literature review.

    abstract:BACKGROUND:The effects of cancer and treatment have severe and long lasting negative impacts on quality of life. Adolescents and Young Adults (AYA) have high survival rates but may not reach their full life potential because of these consequences. This review aims to identify, appraise and synthesise the effects of hea...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2017.02.011

    authors: Bradford NK,Chan RJ

    更新日期:2017-04-01 00:00:00

  • Intraperitoneal chemotherapy in ovarian cancer.

    abstract::From a theoretical viewpoint, intraperitoneal therapy (IP) in patients with ovarian cancer, a malignancy which remains mainly confined to the peritoneal cavity, is logical. Over the past decades this approach has evolved into a therapeutic strategy for a selected group of patients. Data available at present suggest a ...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章

    doi:10.1053/ctrv.1999.0152

    authors: Hofstra LS,de Vries EG,Mulder NH,Willemse PH

    更新日期:2000-04-01 00:00:00

  • Pediatric sarcomas and related tumors of the head and neck.

    abstract::Sarcomas of the head and neck region are a rare group of tumors in children and present challenges with regard to evaluation and treatment. Rhabdomyosarcomas are the most common sarcomas of the head and neck in children. Presence of metastases and complete surgical resectability continue to be the most relevant clinic...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2011.04.005

    authors: Huh WW,Fitzgerald N,Mahajan A,Sturgis EM,Beverly Raney R,Anderson PM

    更新日期:2011-10-01 00:00:00

  • Targeted therapies in advanced differentiated thyroid cancer.

    abstract::Differentiated thyroid cancer is the most common endocrine malignancy, and its incidence has been rising rapidly over the past 10 years. Although most patients with this disease have an excellent prognosis, a subset develops a more aggressive disease phenotype refractory to conventional therapies. Until recently, ther...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2015.06.002

    authors: Carneiro RM,Carneiro BA,Agulnik M,Kopp PA,Giles FJ

    更新日期:2015-09-01 00:00:00

  • Evidence-based use of taxanes in the adjuvant setting of breast cancer. A review of randomized phase III trials.

    abstract::Six major randomized clinical trials evaluating the role of taxanes in the adjuvant setting of breast cancer have demonstrated significant improvements in terms of efficacy in favour of the taxane treatment arm. In all cases, different anthracycline-based regimens were used as the control arm. Nevertheless, many clini...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2007.04.006

    authors: Estévez LG,Muñoz M,Alvarez I,Fernández Y,García-Mata J,Ruiz-Borrego M,Tusquets I,Seguí MA,Rodríguez-Lescure A,Adrover E,Lluch A

    更新日期:2007-08-01 00:00:00

  • Combating melanoma: the use of photodynamic therapy as a novel, adjuvant therapeutic tool.

    abstract::Metastatic malignant melanoma remains one of the most dreaded skin cancers worldwide. Numerous factors contribute to its resistance to hosts of treatment regimes and despite significant scientific advances over the last decade in the field of chemotherapeutics and melanocytic targets, there still remains the need for ...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2010.11.007

    authors: Davids LM,Kleemann B

    更新日期:2011-10-01 00:00:00

  • Microtubule stabilizing agents: their molecular signaling consequences and the potential for enhancement by drug combination.

    abstract::Microtubule stabilization by chemotherapy is a powerful weapon in the war against cancer. Disruption of the mitotic spindle activates a number of signaling pathways, with consequences that may protect the cell or lead to its death via apoptosis. Taxol, the first microtubule stabilizing drug to be identified, has been ...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2006.01.004

    authors: Bergstralh DT,Ting JP

    更新日期:2006-05-01 00:00:00

  • Can stereotactic fractionated radiation therapy become the standard of care for early stage non-small cell lung carcinoma.

    abstract::Management of early stages non-small cell lung carcinoma has traditionally been surgery with radiation selected for medically inoperable patients. Recent emergence of stereotactic body radiation therapy allows for delivery of high radiation dose to the tumor while sparing normal lungs. This reviews compares loco-regio...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2008.06.001

    authors: Nguyen NP,Garland L,Welsh J,Hamilton R,Cohen D,Vinh-Hung V

    更新日期:2008-12-01 00:00:00

  • Maintenance treatment of recurrent ovarian cancer: Is it ready for prime time?

    abstract::Approximately 1% of women in the United States will be diagnosed with epithelial ovarian cancer (EOC) during their lifetime. It is most likely to present at a more advanced stage, requiring aggressive therapeutic measures, and most women will succumb to this illness. Due to advancements in therapy, the oncology commun...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2018.06.001

    authors: DiSilvestro P,Alvarez Secord A

    更新日期:2018-09-01 00:00:00

  • Adjuvant immunotherapy for non-small cell lung cancer.

    abstract::Non-small cell lung cancer (NSCLC) is the biggest cancer killer in the United States and worldwide. In 2011, there are estimated to be 221,130 new cases of lung cancer in the United States. Over a million people will die of lung cancer worldwide this year alone. When possible, surgery to remove the tumor is the best t...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2011.11.008

    authors: Tucker ZC,Laguna BA,Moon E,Singhal S

    更新日期:2012-10-01 00:00:00

  • The role of bone markers in metastatic bone disease.

    abstract::Patients with advanced cancer often develop bone metastases that lead to significant skeletal morbidity and substantially reduced functionality and autonomy [Coleman RE, Rubens RD. Bone metastases. In: Clinical Oncology, 2nd edn. New York: Churchill Livingstone. 2004, p. 1091-128]. As current methods of diagnosing bon...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/s0305-7372(06)80001-0

    authors: Coleman RE

    更新日期:2006-01-01 00:00:00

  • Rationale for the treatment of solid tumors with the proteasome inhibitor bortezomib.

    abstract::Given its role in cellular metabolism, the proteasome could prove to be a critical target that can be exploited in treating cancer. In preclinical studies, several mechanisms for bortezomib's activity in multiple myeloma cells have been identified (e.g., NF-kappaB inhibition); antitumor activity with bortezomib has be...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/s0305-7372(03)00079-3

    authors: Cusack JC

    更新日期:2003-05-01 00:00:00

  • Immunomodulation therapy in colorectal carcinoma.

    abstract::There has been much progress in the understanding of the relationship between the immune system and colorectal cancer. This has led to the use of immunomodulatory therapy in the adjuvant and palliative treatment of the condition. Although attempts at the use of non-specific immunomodulation with agents such as levamis...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1053/ctrv.1999.0160

    authors: Yip D,Strickland AH,Karapetis CS,Hawkins CA,Harper PG

    更新日期:2000-06-01 00:00:00

  • Second-line treatment options in metastatic castration-resistant prostate cancer: a comparison of key trials with recently approved agents.

    abstract::Standard first-line treatment for metastatic castration-resistant prostate cancer (mCRPC) is docetaxel plus prednisone; however, patients will usually experience disease progression during or after docetaxel treatment due to inherent or acquired resistance. Before 2010, second-line options for mCRPC were limited. Howe...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2013.06.008

    authors: Bahl A,Masson S,Birtle A,Chowdhury S,de Bono J

    更新日期:2014-02-01 00:00:00

  • Response to chemotherapy after relapse in patients with or without previous adjuvant chemotherapy for breast cancer. The French Epirubicin Study Group.

    abstract::The French Epirubicin Study Group undertook a retrospective study to evaluate the response rate at relapse, time to treatment failure, and overall survival according to previous CMF-type adjuvant chemotherapy in patients who had taken part in two successive clinical trials. The statistical significance of the comparis...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章

    doi:10.1016/0305-7372(93)90004-b

    authors: Bonneterre J,Mercier M

    更新日期:1993-04-01 00:00:00

  • Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence.

    abstract::Hepatocellular carcinoma (HCC) is the most common primary liver cancer, representing the sixth leading cause of cancer and the third leading cause of cancer-related mortality. Patient stratification and treatment allocation are based on tumor stage, liver function, and performance status. According to the Barcelona Cl...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2018.11.002

    authors: Raoul JL,Forner A,Bolondi L,Cheung TT,Kloeckner R,de Baere T

    更新日期:2019-01-01 00:00:00

  • Adjuvant radiotherapy after radical prostatectomy: evidence and analysis.

    abstract::Although surgery provides excellent control for localized prostate cancer, pathologic examination of more than one-third of specimens will reveal positive surgical margins, seminal vesicle invasion, and/or extracapsular extension, thus putting these patients at increased risk of cancer recurrence. "Adjuvant" radiother...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2010.07.001

    authors: Raldow A,Hamstra DA,Kim SN,Yu JB

    更新日期:2011-04-01 00:00:00

  • Cancer surgery: the last 25 years.

    abstract::Surgery is, and always has been, the main treatment modality of solid tumours. For a long period, it consisted of a number of surgical procedures dictated by basic oncologic principles, most of which are still adhered to. Over the last few decades, increased understanding of the disease, new or improved diagnostic fac...

    journal_title:Cancer treatment reviews

    pub_type: 历史文章,杂志文章,评审

    doi:10.1053/ctrv.1999.0147

    authors: Bremers AJ,Rutgers EJ,van de Velde CJ

    更新日期:1999-12-01 00:00:00

  • The use of haemoregulatory peptides (pEEDCK monomer and dimer) for reduction of cytostatic drug induced haemopoietic damage.

    abstract::We have previously shown that the stem cell inhibitory peptide pGlu-Glu-Asp-Cys-Lys (pEEDCK monomer) leads to a good tolerance of otherwise lethal multiple ara-C doses and an increased survival of ara-C + peptide treated mice. This effect was due to the prevention of drug-induced CFU-S proliferation, thus keeping stem...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/0305-7372(90)90068-q

    authors: Paukovits WR,Moser MH,Binder KA,Paukovits JB

    更新日期:1990-09-01 00:00:00

  • Hexamethylmelamine for the treatment of ovarian cancer--the Mount Sinai experience.

    abstract::Two regimens were tested, CHAP I and CHAP II, the latter, a hexamethylmelamine dosage-intensive regimen, first as second line (salvage) therapy and then as primary therapy. Both produced the most successful results achieved in the Mount Sinai series up to the time of their introduction, when compared to their predeces...

    journal_title:Cancer treatment reviews

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1016/0305-7372(91)90025-u

    authors: Bruckner HW,Cohen C,Mandeli J,Chesser MR,Kabakow B,Wallach R,Holland J

    更新日期:1991-03-01 00:00:00

  • Treatment of advanced pancreatic cancer: from gemcitabine single agent to combinations and targeted therapy.

    abstract::The prognosis of advanced pancreatic adenocarcinoma is still poor nowadays. Gemcitabine in monotherapy (30-min infusion) has been the standard of treatment during the last decade, and many clinical trials have failed to demonstrate an improvement in overall survival (OS) with the addition of different drugs to gemcita...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2008.11.007

    authors: Rivera F,López-Tarruella S,Vega-Villegas ME,Salcedo M

    更新日期:2009-06-01 00:00:00

  • Gender and survival in malignant tumours.

    abstract:BACKGROUND:Epidemiological evidence supports the existence of a survival advantage for female patients with melanoma. This survival advantage often persists when other prognostic variables are taken into account. The basis for this female advantage or male disadvantage is not established although female sex steroids ca...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1053/ctrv.2001.0220

    authors: Molife R,Lorigan P,MacNeil S

    更新日期:2001-08-01 00:00:00

  • Management of brain metastasized non-small cell lung cancer (NSCLC) - From local treatment to new systemic therapies.

    abstract::Lung cancer has the highest frequency of brain dissemination compared to all other solid tumours. Classical treatment options such as brain irradiation have started to be questioned due to lack of survival benefit and risk for severe side effects. Oncogenic driven tumours have the highest frequency of brain disseminat...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2017.02.004

    authors: Tsakonas G,De Petris L,Ekman S

    更新日期:2017-03-01 00:00:00